Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information

v3.8.0.1
Note 11 - Segment Information
 6 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
11.
Segment Information:
 
The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition
accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses.
 
The following is financial information relating to the Company's reportable segments (in thousands):
 
   
Quarter Ended
    
Six M
onths Ended
  
   
December 31,
    
December 31,
  
   
2017
    
2016
    
2017
    
2016
  
Net sales:
                                
Biotechnology
    
101,411
      
85,953
     $
196,487
     $
172,740
  
Protein Platforms
    
29,388
      
21,548
      
54,028
      
41,121
  
Diagnostics
    
23,429
      
24,330
      
48,415
      
48,563
  
Intersegment
    
(75
)
    
(24
)
    
(164
)
    
(36
)
Consolidated net sales
    
154,153
      
131,807
     $
298,766
     $
262,388
  
O
perating income:
                                
Biotechnology
   $
46,210
     $
39,474
     $
90,813
     $
81,594
  
Protein Platforms
    
6,119
      
1,843
      
9,175
      
2,052
  
Diagnostics
    
3,777
      
5,801
      
9,606
      
12,104
  
Segment
operating income
   $
56,106
     $
47,118
     $
109,594
     $
96,110
  
Costs recognized on sale of acquired inventory
    
(264
)
    
(789
)
    
(582
)
    
(2,133
)
Amortization of acquisition related intangible assets
    
(11,296
)
    
(11,627
)
    
(22,675
)
    
(21,815
)
Acquisition related expenses
    
(13,150
)
    
(12,056
)
    
(22,683
)
    
(15,588
)
Stock based compensation
    
(5,044
)
    
(4,055
)
    
(8,839
)
    
(7,245
)
Corporate general, selling, and administrative
expenses
    
(2,204
)
    
(710
)
    
(4,636
)
    
(2,293
)
Consolidated operating
income
    
24,148
      
17,881
     $
50,179
     $
47,036